Similar articles

• Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.

  Kokado Y, Takahara S, Kyo M, Ichimaru N, Toki K, Wang JD, Okuyama A. Kokado Y, et al. Transplant Proc. 1999 Feb-Mar;31(1-2):1151-4. doi: 10.1016/s0041-1345(98)01942-3. Transplant Proc. 1999. PMID: 10083515 No abstract available.
• Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin.

  Kyo M, Ichikawa Y, Hanafusa T, Fukunishi T, Nagano S, Takahara S, Kokado Y, Okuyama A, Ihara H, Ito K, Sagawa S, Sonoda T, Akiyama T, Kurita T, Suzuki S, Amemiya H. Kyo M, et al. Transplant Proc. 1996 Apr;28(2):910-1. Transplant Proc. 1996. PMID: 8623457 No abstract available.
• Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.

  Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO. Alloway RR, et al. Transplant Proc. 1996 Apr;28(2):995-7. Transplant Proc. 1996. PMID: 8623494 Clinical Trial. No abstract available.
• Tacrolimus (FK 506) in kidney transplantation.

  Vanrenterghem Y. Vanrenterghem Y. Transplant Proc. 1998 Aug;30(5):2171-3. doi: 10.1016/s0041-1345(98)00578-8. Transplant Proc. 1998. PMID: 9723431 Review. No abstract available.
• Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression.

  Bush WW. Bush WW. AACN Clin Issues. 1999 May;10(2):253-69; quiz 304-6. doi: 10.1097/00044067-199905000-00011. AACN Clin Issues. 1999. PMID: 10578712 Review.